Identification of site-specific heterogeneity in peptide drugs using intact mass spectrometry with electron transfer dissociation

Rapid Communications in Mass Spectrometry

Volumn 28, Issue 15, 2014, Pages 1757-1763

  Gucinski, Ashley C ^a   Boyne, Michael T ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISSOCIATION; DRUG PRODUCTS; ELECTRON TRANSITIONS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PUBLISHING; SULFUR COMPOUNDS;

BASIC PEPTIDES; ELECTRON TRANSFER DISSOCIATION; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; PEPTIDE DRUGS; RELATED IMPURITIES; SEPARATION METHODS; SITE-SPECIFIC; TANDEM MASS SPECTROMETRY; TANDEM-MASS SPECTROMETRY; TOP-DOWN MASS SPECTROMETRIES;

PEPTIDES;

PROTAMINE;

AMINO ACID SEQUENCE; CHEMISTRY; DRUG CONTAMINATION; DRUG SCREENING; ELECTRON TRANSPORT; ELECTROSPRAY MASS SPECTROMETRY; MOLECULAR GENETICS; PREVENTION AND CONTROL; PROCEDURES; SEQUENCE ANALYSIS; TANDEM MASS SPECTROMETRY;

AMINO ACID SEQUENCE; DRUG CONTAMINATION; DRUG EVALUATION, PRECLINICAL; ELECTRON TRANSPORT; MOLECULAR SEQUENCE DATA; PROTAMINES; SEQUENCE ANALYSIS, PROTEIN; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 84903643027     PISSN: 09514198     EISSN: 10970231     Source Type: Journal    
DOI: 10.1002/rcm.6957     Document Type: Article

References (32)

1. F. Albericio, H. G. Kruger,. Therapeutic peptides. Future Med. Chem. 2012, 4, 1527.
2. B. De Spiegeleer, V. Vergote, A. Pezeshki, K. Peremans, C. Burvenich,. Impurity profiling quality control testing of synthetic peptides using liquid chromatography-photodiode array-fluorescence and liquid chromatography- electrospray ionization-mass spectrometry: the obestatin case. Anal. Biochem. 2008, 376, 229.
3. U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Guidance for Industry: Q3A Impurities in New Drug Substances, 2008.
4. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Impurities in New Drug Substances: Q3A(R2), 2006.
5. S. Van Dorpe, M. Verbeken, E. Wynendaele, B. De Spiegeleer,. Purity profiling of peptide drugs. J. Bioanal. Biomed. 2011, S6, 003.
6. V. Vergote, C. Burvenich, C. Van de Wiele, B. De Spiegeleer,. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach. J. Peptide Sci. 2009, 15, 697.
7. M. Schnolzer, A. Jones, P. F. Alewood, S. B. H. Kent,. Ion-spray tandem mass spectrometry in peptide synthesis: Structural characterization of minor by-products in the synthesis of ACP(65-74). Anal. Biochem. 1992, 204, 335.
8. D. Jain, P. K. Basniwal,. Forced degradation and impurity profiling: recent trends in analytical perspectives. J. Pharmaceut. Biomed. Anal. 2013, 86, 11.
9. M. Verbeken, S. Suleman, B. Baert, E. Vangheluwe, S. Van Dorpe, C. Burvenich, L. Duchateau, F. H. Jansen, B. De Spiegeleer,. Stability-indicating HPLC-DAD/UV-ESI/MS impurity profiling of the anti-malarial drug lumefantrine. Malar. J. 2011, 10, 51.
10. W. P. Kelley, S. Chen, P. D. Floyd, P. Hu, S. G. Kapsi, A. S. Kord, M. Sun, F. G. Vogt,. Analytical characterization of an orally-delivered peptide pharmaceutical product. Anal. Chem. 2012, 84, 4357.
11. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: Analytical Procedures and Methods Validation, 2000.
12. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products: Q6B, 1999.
13. C. Govaerts, E. Adams, A. Van Schepdael, J. Hoogmartens,. Hyphenation of liquid chromatography to ion trap mass spectrometry to identify minor components in polypeptide antibiotics. Anal. Bioanal. Chem. 2003, 377, 909.
14. M. Verbeken, E. Wynendaele, R. A. Lefebvre, E. Goosens, B. De Spiegeleer,. The influence of peptide impurity profiles on functional tissue-organ bath response: The 11-mer peptide INSL6[151-161] case. Anal. Biochem. 2012, 421, 547.
15. T. A. Gill, D. S. Singer, J. W. Thompson,. Purification and analysis of protamine. Process Biochem. 2006, 41, 1875.
16. United States Pharmacopeia and National Formulary (USP 36-NF 31). Protamine Sulfate for Injection. United States Pharmacopeia, Rockville, MD, 2011.
17. A. Syncerski, J. Dudkiewics-Wilczynska, J. Tautt,. Determination of protamine sulphate in drug formulations using high performance liquid chromatography. J. Pharmaceut. Biomed. Anal. 1998, 18, 907.
18. 1H NMR, capillary electrophoresis, and strong-anion-exchange-HPLC for contamination by over sulfated chondroitin sulfate. J. Pharmaceut. Biomed. Anal. 2010, 51, 921.
19. D. Awotwe-Otoo, C. Agarabi, D. Keire, S. Lee, A. Raw, L. Yu, M. J. Habib, M. A. Khan, R. B. Shah,. Physicochemical characterization of complex drug substances: Evaluation of structural similarities and differences of protamine sulfate from various sources. AAPS J. 2012, 14, 619
20. C. Jia, L. Hui, W. Cao, C. B. Lietz, X. Jiang, R. Chen, A. D. Catherman, P. M. Thomas, Y. Ge, N. L. Kelleher, L. Li,. High-definition de novo sequencing of crustacean hyperglycemic hormone (CHH)-family neuropeptides. Mol. Cell. Proteomics 2012, 11, 1951.
21. C. Jia, Q. Yu, J. Wang, L. Li,. Qualitative and quantitative top-down mass spectral analysis of crustacean hyperglycemic hormones in response to feeding. Proteomics 2014, 14, 1185.
22. T. Ando, K. Iwai, S. Ishii, M. Azegami, C. Nakahara,. The chemical structure of one component of clupeine. Biochim. Biophys. Acta 1962, 56, 628.
23. M. Azegami, S. Ishii, T. Ando,. Studies on protamines XIV. Partial chemical structure of one component of clupeine, clupeine Z. J. Biochem. 1970, 67, 523.
24. K. Iwai, C. Nakahara, T. Ando,. Studies on protamines XV. The complete amino acid sequence of the Z component of clupeine. Application of N→O acyl rearrangement and selective hydrolysis in sequence determination. J. Biochem. 1971, 69, 493.
25. K. Suzuki, T. Ando,. Studies on protamines XVI. The complete amino acid sequence of clupeine YII. J. Biochem. 1972, 72, 1419.
26. K. Suzuki, T. Ando,. Studies on protamines XVII. The complete amino acid sequence of clupeine YI. J. Biochem. 1972, 72, 1433.
27. J. E. Syka, J. J. Coon, M. J. Schroeder, J. Shabanowitz, D. F. Hunt,. Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry. Proc. Natl. Acad. Sci. USA 2004, 101, 9528.
28. A. C. Gucinski, M. T. Boyne 2nd,. Evaluation of intact mass spectrometry for the quantitative analysis of protein therapeutics. Anal. Chem. 2012, 84, 8045.
29. P. Y. I. Shek, J. Zhao, Y. Ke, K. W. M. Siu, A. C. Hopkinson,. Fragmentations of protonated arginine, lysine, and their methylated derivatives: Concomitant losses of carbon monoxide or carbon dioxide and an amine. J. Phys. Chem. A 2006, 110, 8282.
30. A. R. Dongre, J. L. Jones, A. Somogyi, V. H. Wysocki,. Influence of peptide composition, gas-phase basicity, and chemical modification on fragmentation efficiency: Evidence for the mobile proton model. J. Am. Chem. Soc. 1996, 118, 8365.
31. L. M. Mikesh, B. Ueberheide, A. Chi, J. J. Coon, J. E. P. Syka, J. Shabanowitz, D. F. Hunt,. The utility of ETD mass spectrometry in proteomic analysis. Biochim. Biophys. Acta 2006, 1764, 1811.
32. T. Tobita, M. Yamasaki, T. Ando,. XII. Determination of the carboxyl-terminal structure of clupeine and salmine using enzymatic procedures. J. Biochem. 1968, 63, 119.